Browsing Tag
Eli Lilly and Company
166 posts
Eli Lilly ($LLY) surges past $1.07tn as EU oncology win and Medicare GLP-1 program align with analyst upgrade
Eli Lilly NYSE LLY surges 6.3 percent to record $1,208.12 on EU Jaypirca approval, Medicare GLP-1 Bridge Program and Leerink price target raise. Read more.
Could one hair loss antibody make Absci’s AI drug platform harder to ignore?
Absci’s ABS-201 data and $100 million raise sharpen ABSI’s AI biologics story across androgenetic alopecia, endometriosis and platform validation.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
Why Pfizer’s CFO exit raises fresh questions about debt, deals and obesity strategy
Dave Denton’s departure leaves Pfizer searching for a permanent chief financial officer while it works to integrate major acquisitions, reduce leverage and prove that its oncology and obesity investments can replace declining mature-product revenue.
Could Ebglyss’ longer dosing window strengthen Eli Lilly and Company’s dermatology growth strategy?
Find out how Ebglyss’ every-eight-week FDA approval could strengthen Eli Lilly’s dermatology strategy and investor sentiment.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Eli Lilly’s oral GLP-1 Foundayo gains new women’s health angle with menopause weight-loss data
Lilly’s oral GLP-1 now targets menopause-linked weight gain. Read why Foundayo could sharpen the next obesity drug battleground.
Is Eli Lilly (LLY) building the obesity drug supply chain nobody else can easily match?
Lilly’s obesity pipeline needs industrial muscle. Its $4.5bn Indiana bet shows why manufacturing may decide the next GLP-1 race.
How VERVE-102 could accelerate the transition from chronic lipid therapy to genomic medicine
Could VERVE-102 shift cholesterol treatment from chronic therapy to one-time gene editing? Explore Eli Lilly and Company’s genomic medicine strategy.